Pathology of Premalignant and Malignant Disease of the Esophagus

  • Jessica Tracht
  • Brian S. Robinson
  • Alyssa M. KrasinskasEmail author


Esophageal adenocarcinoma and squamous cell carcinoma are associated with defined risk factors and tend to develop over time with progression from normal to pre-neoplasia to neoplasia and frank malignancy. In this chapter, we review the pathology of esophageal adenocarcinoma and its precursor lesions, Barrett’s esophagus, and Barrett’s-associated dysplasia. We also review squamous cell carcinoma and squamous dysplasia. We discuss how biopsy, endoscopic mucosal resection, and esophagectomy specimens are assessed, including the challenges in diagnosis and pathologic staging of these specimens. Finally, we touch upon theragnostic tests, including HER2, microsatellite instability, and PD-L1, that are performed in the pathology laboratory and provide information that identified patients who will benefit most from these targeted therapies.


Esophageal cancer Esophageal pathology Barrett’s esophagus Intestinal metaplasia Targeted therapy 


  1. 1.
    Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12. Scholar
  2. 2.
    American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.Google Scholar
  3. 3.
    Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97(8):1930–6. Scholar
  4. 4.
    Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer. 2000;83(1):127–32. Scholar
  5. 5.
    Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, Brown LM, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53. Scholar
  6. 6.
    de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030–6. Scholar
  7. 7.
    el-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin N Am. 2002;31(2):421–40. viii.CrossRefGoogle Scholar
  8. 8.
    Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.CrossRefGoogle Scholar
  9. 9.
    Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1(5):329–38. Scholar
  10. 10.
    Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, Baumgart DC. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108(2):200–7. Scholar
  11. 11.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;111(1):30–50.; quiz 1. Scholar
  12. 12.
    Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42. Scholar
  13. 13.
    Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, Arai T. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion. 2009;80(4):248–57. Scholar
  14. 14.
    Byrne JP, Bhatnagar S, Hamid B, Armstrong GR, Attwood SE. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol. 1999;94(1):98–103. Scholar
  15. 15.
    Glickman JN, Spechler SJ, Souza RF, Lunsford T, Lee E, Odze RD. Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2009;33(6):818–25. Scholar
  16. 16.
    Anders M, Lucks Y, El-Masry MA, Quaas A, Rosch T, Schachschal G, Bahr C, et al. Subsquamous extension of intestinal metaplasia is detected in 98% of cases of neoplastic Barrett’s esophagus. Clinical Gastroenterol Hepatol. 2014;12(3):405–10. Scholar
  17. 17.
    Yachimski P, Shi C, Slaughter JC, Washington MK. Endoscopic mucosal resection of Barrett’s esophagus detects high prevalence of subsquamous intestinal metaplasia. World J Gastrointest Endosc. 2013;5(12):590–4. Scholar
  18. 18.
    Dunbar KB, Spechler SJ. Controversies in Barrett esophagus. Mayo Clin Proc. 2014;89(7):973–84. Scholar
  19. 19.
    Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2009.Google Scholar
  20. 20.
    Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, et al., editors. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.Google Scholar
  21. 21.
    Chinyama CN, Marshall RE, Owen WJ, Mason RC, Kothari D, Wilkinson ML, Sanderson JD. Expression of MUC1 and MUC2 mucin gene products in Barrett’s metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology. 1999;35(6):517–24.CrossRefGoogle Scholar
  22. 22.
    Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett’s) metaplasia. Mod Pathol. 2004;17(10):1282–8. Scholar
  23. 23.
    Guillem P, Billeret V, Buisine MP, Flejou JF, Lecomte-Houcke M, Degand P, Aubert JP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer. 2000;88(6):856–61.CrossRefGoogle Scholar
  24. 24.
    Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003;27(11):1442–7.CrossRefGoogle Scholar
  25. 25.
    Srivastava A, Appelman H, Goldsmith JD, Davison JM, Hart J, Krasinskas AM. The use of ancillary stains in the diagnosis of Barrett esophagus and Barrett Esophagus-associated dysplasia: recommendations from the Rodger C. Haggitt gastrointestinal pathology society. Am J Surg Pathol. 2017;41(5):e8–e21. Scholar
  26. 26.
    Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, et al. TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55(10):1390–7. Scholar
  27. 27.
    Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, et al. Novel staining pattern of p53 in Barrett’s dysplasia – the absent pattern. Histopathology. 2010;57(6):933–5. Scholar
  28. 28.
    Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50(7):920–7. Scholar
  29. 29.
    Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30. Scholar
  30. 30.
    Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, Offerhaus GJ, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–6. Scholar
  31. 31.
    Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50(1):23–6.CrossRefGoogle Scholar
  32. 32.
    Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007;31(11):1719–25. Scholar
  33. 33.
    Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-Kenudson M, Lauwers GY. Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol. 2009;33(4):620–5. Scholar
  34. 34.
    Kumarasinghe MP, Brown I, Raftopoulos S, Bourke MJ, Charlton A, de Boer WB, Eckstein R, et al. Standardised reporting protocol for endoscopic resection for Barrett oesophagus associated neoplasia: expert consensus recommendations. Pathology. 2014;46(6):473–80. Scholar
  35. 35.
    Vieth M, Stolte M. Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol. 2005;19(6):857–69. Scholar
  36. 36.
    Edge SB, Compton CC, et al., editors. AJCC cancer staging manual. New York: Springer-Verlag; 2009.Google Scholar
  37. 37.
    Dry SM, Lewin KJ. Esophageal squamous dysplasia. Semin Diagn Pathol. 2002;19(1):2–11.PubMedGoogle Scholar
  38. 38.
    Shimizu M, Ban S, Odze RD. Squamous dysplasia and other precursor lesions related to esophageal squamous cell carcinoma. Gastroenterol Clin N Am. 2007;36(4):797–811., v-vi. Scholar
  39. 39.
    Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190(5):562–72; discussion 72-3CrossRefGoogle Scholar
  40. 40.
    Dawsey SM, Fagundes RB, Jacobson BC, Kresty LA, Mallery SR, Paski S, van den Brandt PA. Diet and esophageal disease. Ann N Y Acad Sci. 2014;1325(1):127–37. Scholar
  41. 41.
    Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(6):822–7. Scholar
  42. 42.
    O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol: WJG. 2013;19(35):5806–12. Scholar
  43. 43.
    Iwaya T, Maesawa C, Ogasawara S, Tamura G. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. Gastroenterology. 1998;114(6):1206–10.CrossRefGoogle Scholar
  44. 44.
    Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, Rajendra S, Streutker CJ, Vajpeyi R, Wang B. Infection and esophageal cancer. Ann N Y Acad Sci. 2014;1325(1):187–96. Scholar
  45. 45.
    Takubo K, Fujii S. Squamous cell carcinoma of the oesophagus. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumors: digestive system. 5th ed. Lyon: WHO Press; 2019. p. 36–7.Google Scholar
  46. 46.
    Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232(2):225–32.CrossRefGoogle Scholar
  47. 47.
    Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus. 2011;24(1):33–8. Scholar
  48. 48.
    Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, et al. SEER cancer statistics review 1975–2010. Bethesda, MD: National Cancer Institute. (, based on November 2012 SEER data submission, posted to the SEER Web site, April 2013)
  49. 49.
    Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol. 2014;6(10):403–6. Scholar
  50. 50.
    Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106(10):2119–27. Scholar
  51. 51.
    Chang F, Deere H, Mahadeva U, George S. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol. 2008;129(2):252–62. Scholar
  52. 52.
    Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31(1):58–64. Scholar
  53. 53.
    Hermann RM, Horstmann O, Haller F, Perske C, Christiansen H, Hille A, Schmidberger H, et al. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use? Dis Esophagus. 2006;19(5):329–34. Scholar
  54. 54.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. Scholar
  55. 55.
    Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(4):446–64. Scholar
  56. 56.
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. , V.4.2017. Accessed 10 Feb 2018.
  57. 57.
    Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012;18(2):546–54. Scholar
  58. 58.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, et al. PD-1 blockade in Tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. Scholar
  59. 59.
    Meltzer SJ, Yin J, Manin B, Rhyu MG, Cottrell J, Hudson E, Redd JL, et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett’s-associated esophageal adenocarcinomas. Cancer Res. 1994;54(13):3379–82.PubMedGoogle Scholar
  60. 60.
    Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. Scholar
  61. 61.
    Curea FG, Hebbar M, Ilie SM, Bacinschi XE, Trifanescu OG, Botnariuc I, Anghel RM. Current targeted therapies in HER2-positive gastric adenocarcinoma. Cancer Biother Radiopharm. 2017;32(10):351–63. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Jessica Tracht
    • 1
  • Brian S. Robinson
    • 1
  • Alyssa M. Krasinskas
    • 1
    Email author
  1. 1.Department of Pathology and Laboratory MedicineEmory UniversityAtlantaUSA

Personalised recommendations